# PR19 (NCT02960087)

> Phase II High Dose Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02960087
- Phase: NA
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Canadian Cancer Trials Group
- Conditions: Prostate Carcinoma
- Interventions: Low dose rate brachytherapy; High dose rate brachytherapy
- Enrollment: 334
- Primary outcome: Efficacy of HDR and LDR brachytherapy on prostate cancer control as defined by 48 month PSA values

## Indexed commentary on PR19 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 12

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=pr19-nct02960087

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02960087", "email": "<work email>"}; the inbox owner confirms by the emailed link.